美通社

2024-09-09 19:46

Sirsram Medical announces NMPA approval for DAXXIFY®

Marking the introduction of the world's first and only peptide-powered  botulinum toxin product to Mainland China

HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions announced today that the National Medical Products Administration has accepted the Biologics License Application ("BLA") for the Company's botulinum toxin, DAXXIFY® (Chinese trademark: 达希斐®), intended for the temporary improvement in the appearance of moderate to severe glabellar lines caused by movements associated with corrugator and/or procures muscle activity in adult patients. As the first innovation of its kind in over 20 years, DAXXIFY® brings together botulinum toxin and Revances's proprietary Peptide Exchange Technology™ (PXT) to deliver outstanding efficacy.

Results from DAXXIFY® can be seen as early as day following treatment for some people, and typically within 2 days. The treatment is also considered long-lasting and keeps frown lines smoother with the convenience of as few as 2 treatments a year, and results slowly soften over a prolonged period of time. Additionally, DAXXIFY® is known to result in a better look to skin texture after treatment, smoothing even the deepest lines.

Alongside its outstanding clinically proven results, the high-end injectable botulinum toxin offers high safety. Free of human albumin or animal-based components, it has a lower probability of neutralizing antibodies or allergic reactions occurring during treatment sessions. DAXXIFY® also provides practitioners with more convenient and controllable storage management, aligning with clinic day operations. It can be kept at room temperature below 25°C, and after reconstitution, it can be stored in a refrigerator at 2°C-8°C, protected from light for 72 hours.

The registration of DAXXIFY® in Mainland China is a landmark milestone for Sisram's injectable business block, which strengthens the Company's comprehensive wellness ecosystem and represents a solid foundation for future commercialization in these strategic territories.

Alongside a license agreement granting exclusive rights to import, sell, and commercialize DAXXIFY® in Mainland China, Hong Kong SAR, and Macao SAR, the Company's comprehensive injectables portfolio includes partnerships with IBSA for the dermal biostimulator Profhilo® in other APAC markets, and with Prollenium® for its renowned dermal filler collection, FDA & CE approved Revanesse®, in several key markets including Germany, Austria, Switzerland, Australia, New Zealand, and Japan, with potential expansion into other regions.

The market value of the injectable segment in China has significantly soared, reaching an estimated value of RMB33.3 billion in recent years. According to the Company, this pivotal achievement serves as a competitive advantage, creating a significant new driver for revenues and laying a new cornerstone for business development.

Mr. Liu Yi, Sisram Chairman and Executive Director, said, "China has always been a strategic market for Sisram, and the approval of DAXXIFY® serves as a key milestone for bringing Sisram's high-end injectables portfolio to Mainland China."

"From a business perspective, this achievement enhances the competitiveness of the Company's products, expanding its diversified offerings and delivering an innovative experience for beauty-seeking patients," he added.

"We are committed to building lasting Partner-Patient relationships by delivering clinical excellence and outstanding patient experiences. The recent approval of DAXXIFY® represents a significant advancement in our offerings, providing consumers with a longer-lasting and safer treatment option and aligning perfectly with practitioners' needs for greater flexibility and convenience in their management practices," said Lior Dayan, CEO of Sisram and Alma.

He continued, "Sisram will continue to enhance our diversified product portfolio, reinforcing our mission to improve patients' quality of life and prioritize the customer journey as a key driver of our long-term success."

Note:

①     Based on pooled patient diary data from SAKURA 1 and SAKURA 2
②     At least 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator's and patient's assessments.
③     Median time to return to baseline wrinkle severity was 27.7 weeks in SAKURA 1 and 26 weeks in SAKURA 2
④     64% of patients achieved an improvement in the appearance of skin texture at week 2 from a post hoc analysis of a phase 2 study with 60 patients

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused branding, ranging from Energy Based Devices, injectables, aesthetics and digital dentistry, personal care and more. The Company is majority-owned by Fosun Pharma, one of China's leading healthcare groups. Sisram Medical went public on the Main Board of the Hong Kong Exchange in September 2017.

Sisram Medical – Enhancing Quality of Life

http://www.sisram-medical.com

source: Sisram Medical Ltd

《說說心理話》親友自殺離世遺屬如何自處?身邊親友應該怎樣陪他們走出人生最低谷?► 即睇

人氣文章
最近7天
1
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
2
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
3
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
4
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
5
高息定存 | 信銀國際12個月港元定存高達3.5厘
6
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
7
David Webb:因病情惡化,將有序結束個人財經網站
8
港股 | 蕭猷華:恒指短線回調,中線繼續看好
9
iPhone SE 4或於本周內上架官網
10
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
一本萬利 | 2025年的五個「勿」(有片)
10
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
11
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
16
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
17
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
18
習近平應約與特朗普通電話,特:冀盡快與習見面
19
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
20
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
21
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
22
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
23
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
24
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
25
特朗普就職 | 特朗普上台後行動列表
26
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
27
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
28
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
29
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
30
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老